Enanta Pharmaceuticals Inc SEC Filings

Enanta Pharmaceuticals (ENTA) reported an equity compensation grant to its Vice President, Finance, who is its principal financial officer. On 11/25/2025, the officer received 6,463 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing direct beneficial ownership of common stock to 17,375 shares following the transaction. The RSUs vest 25% on December 1, 2026, then in substantially equal annual installments over the next three anniversaries.

The filing also reports a grant of a stock option for 12,925 shares of common stock at an exercise price of $13.66 per share, expiring on 11/25/2035. This option becomes exercisable in substantially equal quarterly installments over four years from the grant date of November 25, 2025, resulting in 12,925 derivative securities beneficially owned after the transaction, all held directly.

Enanta Pharmaceuticals (ENTA) reported a new equity award to an executive officer. The filing shows the Chief Product Strategy Officer received a stock option to buy 100,000 shares of Enanta common stock at an exercise price of $13.66 per share, granted on November 25, 2025.

The option becomes exercisable in substantially equal quarterly installments over four years from the grant date, with any fractional shares carried forward to the next period, and expires on November 25, 2035. Following this grant, the reporting person beneficially owns 100,000 derivative securities directly in the form of this stock option.

Enanta Pharmaceuticals Inc. (ENTA) reported a stock option grant to its Chief Scientific Officer on a Form 4. On November 25, 2025, the officer received a stock option to purchase 110,000 shares of Enanta common stock at an exercise price of $13.66 per share, expiring on November 25, 2035.

The option covers 110,000 underlying shares of common stock and is held directly. It becomes exercisable, subject to continued employment, in substantially equal quarterly installments over four years from the grant date, with fractional shares cumulated and becoming exercisable once a whole share equivalent is reached.

Enanta Pharmaceuticals Inc. (ENTA) reported a new equity award to its President and CEO, who also serves as a director. On November 25, 2025, the insider received a stock option to purchase 310,000 shares of Enanta common stock at an exercise price of $13.66 per share, expiring on November 25, 2035.

The option is scheduled to become exercisable in substantially equal quarterly installments over four years from the grant date, subject to the optionholder’s continued employment. Following this grant, the reporting person beneficially owns 310,000 derivative securities directly in the form of this stock option.

Enanta Pharmaceuticals, Inc. (ENTA) files its annual report describing a virology- and immunology-focused biotech business built on small-molecule drug discovery. The company already earns double-digit royalties from AbbVie’s HCV regimen MAVYRET/MAVIRET, driven by Enanta’s protease inhibitor glecaprevir, and has received $954 million in cumulative royalties through September 30, 2025. In April 2023 it sold 54.5% of future MAVYRET/MAVIRET royalties through June 2032 to an OMERS affiliate for $200 million, subject to a 1.42x cap.

Enanta reports $188.9 million in cash, cash equivalents and short-term marketable securities as of September 30, 2025 and expects, together with retained HCV royalties and proceeds from an October 2025 equity offering, to fund operations into fiscal 2029. The pipeline is wholly owned and includes two clinical RSV antivirals (zelicapavir and EDP‑323) with positive Phase 2 data, plus preclinical oral programs targeting KIT (EDP‑978) for chronic spontaneous urticaria and STAT6 (EPS‑3903) for atopic dermatitis and other type 2 inflammatory diseases. Management warns that revenue is highly dependent on AbbVie’s HCV sales and that significant additional funding will be required if programs advance as planned.

Enanta Pharmaceuticals, Inc. (ENTA) filed a current report to announce that it released a press release with its financial results for the fiscal quarter and year ended September 30, 2025. The press release, dated November 17, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed numbers and commentary are contained in that exhibit rather than in the body of this report. This filing is a standard earnings disclosure under Item 2.02 of the Exchange Act.

Deep Track entities and David Kroin filed a Schedule 13G disclosing shared beneficial ownership of 1,484,513 shares of Enanta Pharmaceuticals common stock, representing 5.33% of the class based on 27,877,923 shares outstanding. The filing shows shared voting and shared dispositive power over those shares, with no sole voting or dispositive power reported. The holders state the position was not acquired to change or influence control and the filing is a joint filing by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin.

Enanta Pharmaceuticals reported a material event in an 8-K that discloses an Underwriting Agreement dated September 30, 2025, legal opinion and consent from Foley Hoag LLP, and an embedded interactive cover page XBRL file. The filing restates standard forward-looking statement disclaimers and indicates the company will not update forward-looking statements except as required by law. The document is signed by Jay R. Luly, Ph.D., President and Chief Executive Officer, with a filing date of October 1, 2025.

Enanta Pharmaceuticals (ENTA) prospectus supplement describes a securities offering that would issue shares at $10.00 per share with aggregate proceeds shown as $65,000,000 (and an underwriting fee example of $0.60 per share or $3,900,000). Net proceeds are intended to fund clinical trials, research and development, working capital and general corporate purposes. The filing highlights ongoing revenue from an AbbVie collaboration and a 2023 royalty sale that help fund Enanta’s R&D programs. Clinical programs discussed include oral STAT6 inhibitors (a development candidate expected to be nominated in the second half of 2025), zelicapavir safety data showing mostly mild adverse events, and disease burdens for RSV and COVID-19 with specific hospitalization and mortality ranges for RSV in older adults. The supplement details a 60-day lock-up for insiders, exceptions (including Rule 10b5-1 plans), tax withholding rules for non-U.S. holders (generally 30% on dividends absent treaty relief), and references to incorporated reports and underwriting disclosures.